Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386337/
The two authorized anti-SARS-CoV-2 mAbs combinations, bamlanivimab/etesevimab and casirivimab/imdevimab, may have different efficacy against VOCs. Compared to casirivimab/imdevimab, bamlanivimab/etesevimab seems to be associated with an increased risk of hospitalization or death in patients infected with the Gamma variant. The knowledge of infecting SARS-CoV-2 variant may allow a more appropriate use of mAbs.